← Back to Search

Clinical Decision Support Tool

Electronic Medical Record Support for Diabetes Management

N/A

Recruiting

Led By Ariana Pichardo-Lowden, MD

Research Sponsored by Milton S. Hershey Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Children (<18 years)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at whether using an electronic medical record clinical decision support tool can help manage dysglycemia in the hospital and improve outcomes.

Who is the study for?

This trial is for adults over 18 years old with conditions like prediabetes, diabetes, and varying blood sugar levels who are hospitalized or visiting outpatient clinics at specific Penn State Health centers. Children under 18 cannot participate.

What is being tested?

The study is testing an electronic tool that helps doctors make decisions about diabetes care in hospitals. It looks at how the tool affects blood sugar control and its impact on clinical outcomes and costs.

What are the potential side effects?

Since this trial involves a decision support tool rather than medication, traditional side effects are not applicable. However, there may be indirect effects on patient care based on the tool's recommendations.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Average hospital length of stay (LOS)

Secondary study objectives

Average reduction of glycohemoglobin level within 12 months of discharge

Cost of hospitalization

Frequency of Intensive Care unit (ICU) transfers

+17 more

Other study objectives

Provider's decision making

Provider's knowledge

Provider's perspective

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Active Inpatient Diabetes Clinical Decision SupportExperimental Treatment1 Intervention

The Active arm consists of participants treated during the "ON" phase of the GlucAlert-CDS tool. The tool operates through an automated process of rules embedded in the EMR recognizing hypoglycemia (established or impending); recurrent hyperglycemia (in type 1 and 2 DM, or stress hyperglycemia-SH); and inappropriate insulin use (sliding scales monotherapy if recurrent hyperglycemia in type 2 DM or SH, or any time in type 1 DM). If the tool's criteria are met, an alert in the EMR will notify the provider with the clinically recommended treatment.

Group II: Inactive Inpatient Diabetes Clinical Decision SupportActive Control1 Intervention

The Inactive arm consists of participants treated during the "OFF" phase of the GlucAlert-CDS Tool. Alerts will not be sent to provider's

0 / 1Eligibility criteria met